The company’s shares are continuing the week lower.
The post CSL (ASX:CSL) share price slumps despite new board appointment appeared first on The Motley Fool Australia. –
At the time of writing, the global biotech’s shares are down 0.7% to $295.40. In comparison, the S&P/ASX 200 Index (ASX: XJO) is also down 1.06% to 7,502 points.
CSL strengthens its team
Investors appear to be unmoved by the company’s latest news, selling CSL shares ahead of its FY21 full-year results tomorrow.
In today’s release, CSL advised it has appointed Professor Duncan Maskell as an independent non-executive director, effective from 18 August.
Professor Maskell brings a wealth of knowledge from the private sector, particularly in the commercialisation of research initiatives.
He has co-founded several biotech companies such as Arrow Therapeutics and Discuva. Arrow was sold to British-Swedish multinational pharmaceutical and biotechnology giant AstraZeneca while antibiotic innovation company Summit Therapeutics purchased Discuva.
Professor Maskell is currently serving as vice-chancellor of the University of Melbourne. Prior to this, he held the role of senior pro-vice-chancellor at the University of Cambridge in the United Kingdom.
Previously, Professor Maskell also worked at the University of Oxford, Imperial College London and Wellcome Biotech.
CSL chair Dr Brian McNamee AO commented:
Professor Maskell is an exceptional addition to the CSL Board. He brings wide-ranging international experience in science and commerce, developed across a rich 30-year career in research, academia and entrepreneurship. These areas represent the core of what we do at CSL and his contribution will strengthen the Board’s range of experience.
Professor Maskell has a Master of Arts and a Doctor of Philosophy from the University of Cambridge.
About the CSL share price
Over the course of the past 12 months, CSL shares have taken investors on a rollercoaster ride but are up just 5.13%. The company’s shares are currently sitting just above the middle of their 52-week range of $242.00 to $320.42.
On valuation grounds, CSL is the third-largest company on the ASX with a market capitalisation of roughly $134.45 billion.
Should you invest $1,000 in CSL right now?
Before you consider CSL, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
How did the CSL (ASX:CSL) share price respond last earnings season?
ASX 200 Weekly Wrap: New records just keep coming for the ASX 200
If you invested $1,000 in CSL (ASX:CSL) shares a decade ago, here’s what it would be worth now
Here’s why the CSL (ASX:CSL) share price is up 5% in a month
How does the CSL (ASX:CSL) share price perform during lockdowns?
Motley Fool contributor Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.